Table 1.
Trial arm | subgroup | n= | sex (M), % | Rai ≥3, % | Unmut, % | CD38+, % |
---|---|---|---|---|---|---|
≥65 | TN | 17 | 53 | 59 | 53 | 24 |
≥65 | RR | 16 | 50 | 81 | 81 | 56 |
TP53 | TN | 33 | 64 | 61 | 64 | 27 |
TP53 | RR | 14 | 50 | 79 | 71 | 36 |
Both | all | 80 | 56 | 68 | 66 | 34 |
≥65: 65 years of age or older, TP53: TP53 aberrations, TN: treatment naïve, RR: relapsed or refractory, M: male, Unmut: unmutated IGHV (>98% homology to germline), CD38+: >30% of CLL cells express CD38 above isotype control.